Ovarian Cancer Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Hormonal Therapy, Targeted Therapy, and Surgery), Region And Segment Forecasts, 2024-2031
Share With :
The Ovarian Cancer Market is expected to grow at a 10.5% CAGR during the forecast period for 2024-2031.
Ovarian cancer rank fifth in cancer deaths among women and accounting for more deaths than any other cancer of the female reproductive system. Previously it believed that cancer begin only in the ovaries, but recent evidence suggests that many ovarian cancer may start in the fallopian tubes. Factors can increase risk of cancer include older age, genetic mutation such as breast cancer gene 1 (BRCA1) and breast cancer gene 2 (BRCA2) and oestrogen hormone replacement therapy. Based on cell of origin ovarian cancer can categorised into three type epithelial tumors, stromal tumors and germ cell tumors. Epithelial tumors begins epithelia tissue of ovarian and it comprise 90% of the ovarian cancers whereas stromal tumors begin from the hormone-producing cell of the ovaries and consist of 7% of the ovarian cancers. According to global estimate 225,000 new cases were detected each year and 140,000 people annually die from the ovarian cancer.
Treatment of ovarian cancer depending on its type and stage. Two types of treatment offer for a patient with ovarian cancer patients include local treatment and systematic treatment. Local treatment consists of surgery and radiation therapy whereas systematic treatment include chemotherapy, hormone therapy and targeted therapy. Successful development of new targeted therapy and recent approval of Avastin (Bevacizumab) and PARP inhibitor such as rubraca (rucaparib), lynparza (olaparib) and zijula (niraparib) will drive the market in forecast period. Additionally, new understanding of the heterogeneity and biology of disease lead to active development of next-generation chemotherapies, new targeted agents and immune-oncology drugs anticipated to further drive market growth.
In January, 2016 The UK National Institute for Health and Care Excellence (NICE) approve AstraZeneca drug Lynparza (olaparib) to treat women with platinum-sensitive relapsed BRAC-mutated high grade ovarian cancer. In July 2018, on the basis of phase 3 trial dubbed GOG -0213, Roche get expanded reimbursement for ovarian cancer therapy. The Avastin previously gained coverage to be used with carboplatin and paclitaxel as first-line combination treatment for patients with high relapsed ovarian cancer. It was also reimburse for use with topotecan or paclitaxel or PEGylated liposomal doxorubicin in platinum resistance ovarian cancer patient who have not previously treated with VEGF-based therapy.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 10.5% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Treatment |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Pfizer Inc. Fresenius Kabi USA, LLC, Teva Pharmaceuticals USA, Inc., F. Hoffmann-La Roche AG. AstraZeneca, Tesaro Inc. Clovis Oncology, Inc., and Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Ovarian Cancer Market Outlook By Treatment
Global Ovarian Cancer Market Outlook By Region
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.